Release issued 14th March 2005

Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP - News), announced today that it has entered into an agreement with ProEthic Pharmaceuticals, Inc. for the U.S. and Canadian rights to develop and commercialize a once-daily ketoprofen- containing topical patch originally developed by APR Applied Pharma Research s.a. and further licensed to ProEthic.

Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) generally used for the treatment of inflammation and pain and available in the U.S. only in oral form. Currently in Phase II clinical trials in the U.S., the ketoprofen patch is being developed for the localized treatment of acute pain associated with soft- tissue injuries such as tendonitis or joint sprains and strains. Two Phase III placebo-controlled studies in soft-tissue injury and ankle sprains have been completed in Europe by ProEthic's European partner Applied Pharma Research AG, with statistically significant results.

"We believe that the topical ketoprofen patch, which bypasses the bloodstream, could also offer the added benefit of targeted pain control aimed directly at the injury site with the convenience of once-a-day dosing. We would expect that this has the potential to be an attractive product opportunity compared to systemic agents," said Peter A. Lankau, Endo's president and chief operating officer. The total soft-tissue injury market is currently estimated to be approximately $2.5 billion, primarily consisting of NSAID's and COX-II's.

Under the terms of the agreement, Endo will make a $10.0 million upfront payment and payments of approximately $14.0 million for the achievement of certain regulatory milestones.

Endo Pharmaceuticals Holdings Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management products.

(28th July 2009) APR Applied Pharma Research SA. announces the signature of an exclusive licensing agreement with SciClone Pharmaceuticals Inc. for Ondansetron Rapidfilm™ for China and Vietnam

(24th June 2009) Abdi Ibrahim , APR and Labtec GmbH have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey.

(22nd June 2009) FDA has approved Cambia™, Potassium Diclofenac Powder for Oral Solution for the treatment of acute migraine attacks with or without aura, originally developed by APR Applied Pharma Research SA (APR)

(16th February 2009) BioAlliance Pharma Files for European Marketing Authorization for Ondansetron RapidFilm in Supportive Care in Cancer

(17th November 2008) APR and Fidia have received IND approval from FDA for a new NSAID Matrix Patch product